A BETTER TREATMENT & MARKET OPPORTUNITY
Many therapies treat the inflammation of psoriasis by targeting parts of the immune system. While effective, this approach can result in systemic adverse effects. Recensa is taking a different approach. Recensa is targeting oxidative stress, an important factor in the ongoing inflammatory cycle of psoriasis. By activating Nrf2, our investigational small molecule pharmaceuticals can upregulate up to 300 anti-oxidant molecules and reduce oxidative stress within the cells. This reduces the markers of inflammation of psoriasis within the cells of the skin.
tHE NEED FOR BETTER THERAPIES
Millions of those with psoriasis suffer from poor productivity, impaired social relationships, and damaged self-perceptions
THE PSORIASIS MARKET
~7.5 million patients in the United States
-$63.2 billion in direct medical costs
-90% of patients affected by mild-to-moderate psoriasis
EXISTING TREATMENTS FALL SHORT
Corticosteroids are effective at suppressing inflammation. However, they can cause significant adverse effects and have limitations on use in certain body parts. Corticosteroids are also not recommend for long term use, and according to several scientific studies, result in only low to moderate satisfaction.
VITAMIN D ANALOGS
Vitamin D analogs have moderate efficacy in symptom relief, and, similar to corticosteroids, carry limitations on use in certain body parts. While patients report moderate satisfaction, Vitamin D analogs fail to address psoriasis extensively at the molecular level as Recensa's Nrf2 activators do.
RECENSA'S unique approach: Nrf2 activation
UPREGULATION OF Nrf2
THE MASTER CONTROLLER FOR ANTIOXIDANTS withIN THE CELL
Nrf2 is a transcription factor, a type of protein that influences how genetic information is used to produce other proteins. Nrf2 regulates the expression of antioxidant proteins that protect against oxidative damage triggered by injury and inflammation. While normally bound to other proteins, Nrf2 is released into the cell nucleus under conditions of oxidative stress. Research has shown that increasing levels of Nrf2 may be useful for treating diseases that are caused by, or involve, oxidative stress. These include multiple sclerosis, fibrotic liver disease, and many inflammatory diseases, most notably psoriasis.
a BETTER THERAPy is here
Nrf2 has been identified as a key regulator of the antioxidant response in human cells. When activated, it stimulates the release of up to 300 antioxidant molecules. Our developmental topical therapies have been shown in skin models to reduce markers of psoriasis.
Potential benefits of Nrf2 ACTIVATORS
Fewer adverse effects
Use on all parts of the body
Expected high patient satisfaction